Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed

Lucid Diagnostics Inc.

Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
EsoGuard revenue of $1.2M for Q4; GAAP net loss $11.5M ($0.20/share); non-GAAP loss $10.9M ($0.19/share).
Cash and equivalents $22.4M at Dec 31, 2024; pro forma ~$36.9M after Q1 2025 common stock financing.
Secured first commercial coverage from Highmark and first state biomarker agreement with Blue Cross Blue Shield of RI.
Completed $22M convertible debt refinancing and $15.3M stock financing, net proceeds $32.8M, extending cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.